NC 2700

Drug Profile

NC 2700

Alternative Names: NC-2700

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Chemiphar
  • Class Urologics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hyperuricaemia

Highest Development Phases

  • Preclinical Hyperuricaemia

Most Recent Events

  • 29 Nov 2017 Preclinical trials in Hyperuricaemia in Japan
  • 29 Nov 2017 Nippon plans a phase I trial for Hyperuricaemia in Japan
  • 19 Jul 2016 Research programme: hyperuricaemia therapies - Nippon Chemiphar is available for licensing as of 19 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top